Introduction {#sec1}
============

Rheumatoid arthritis (RA) is a relatively common chronic multifactorial autoimmune disorders characterized by progressive damage to joint and tendons, and complications in some case may lead to premature mortality \[[@B1]\]. The etiology of RA remains complex and unknown, but both genetic background and environmental risk factors play a great role in RA risk \[[@B2]\]. The genetic contribution to RA is estimated to be between 50% and 60%, and therefore identification of susceptibility genes is important for understanding the biological mechanisms of RA pathogenesis, etiology, prognosis and outcomes \[[@B7],[@B8]\].

Genome wide association studies (GWAS) involving approximately 2000 patients and 3000 controls revealed that the polymorphism *rs6822844 G/T* of the interleukin-21 (IL-21) gene has been defined as a candidate genetic marker with RA risk \[[@B9]\]. The IL-21 gene, also known as Za11 or CVID11, is located on human chromosome 4q27, and encodes a member of the common-γ chain family of cytokines with immunoregulatory activity \[[@B10]\]. The protein encoded by IL-21 is known to be involved in both innate and adaptive immune responses by inducing the differentiation, proliferation and activity of multiple target cells, including macrophages, natural killer cells, B cells and cytotoxic T cells \[[@B11]\]. Dysregulation of this gene may result in multiple immune-mediated diseases including RA, systemic lupus erythematosus, psoriasis and chronic inflammatory diseases \[[@B15]\].

The *rs6822844* polymorphism locates in the flanking 3′-untranslated region of IL-21 \[[@B18]\], and may regulate the transcription and expression of the IL-21 gene, which may influence the occurrence and progress of RA. Although numbers of studies have evaluated the association between *rs6822844* and RA susceptibility, reported results remain inconsistent \[[@B9],[@B19]\]. At the same time, considering the importance of *rs6822844* G/T polymorphism in pathogenesis of RA, it is necessary and urgent to perform a comprehensive meta-analysis of all case--control studies that included both each genotype and eligible factors such as rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) status and levels.

Materials and methods {#sec2}
=====================

Identification of eligible studies {#sec2-1}
----------------------------------

Searches for published data up to October 20, 2019 were conducted on the PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>) database, without any restriction on language or publication year. The following keywords were used: 'IL-21 or interleukin-21', 'polymorphism or variant', 'rheumatoid arthritis or RA', without any restriction on language or publication year. Using above information, a total of 23 articles were identified. In addition, we also screened references cited in the retrieved articles and other review articles by hand. Studies were selected based on the following inclusion criteria: (1) the study investigated the association between RA and *IL-21 rs6822844* G/T polymorphism; (2) the study was of a case--control design; (3) sufficient genotype numbers (GG, GT and TT) of cases and controls; (4) RF and/or ACPA information was available.

Data extraction {#sec2-2}
---------------

The following information was collected from eligible publications: the last name of first author, year of publication, country of origin, each genotype number in the case and control group, source of control group, Hardy--Weinberg equilibrium (HWE) of controls, and genotyping methods. In addition, RA diagnostic information, such as autoantibody status (RF+/- or ACPA+/-) was also collected.

Quality assessment and Newcastle--Ottawa Scale {#sec2-3}
----------------------------------------------

The quality of the included studies was evaluated by the following five aspects: source of cases, source of controls, specimens used for determining genotypes, total sample size and HWE in controls. The quality scores ranged from 0 to 15, higher scores indicating better quality. Reports scoring \<10 were classified as 'low quality' and those ≥10 as 'high quality' \[[@B27]\]. Besides, the Newcastle--Ottawa Scale (NOS) was also used to assess the quality of each study. This measure assesses observational studies on measures of study quality, such as the selection of cases, comparability of populations and ascertainment of exposure to risks. The NOS ranges from 0 (worst) to 9 stars (best) \[[@B28]\]. Studies with a score of ≥7 stars were considered as high-quality.

Statistical analysis {#sec2-4}
--------------------

Odds ratio (OR) with 95% confidence interval (CI) were used to measure the strength of the association between *IL-21 rs6822844 G/T* polymorphism and RA. The status of RF and ACPA was classified into four categories namely, RF-positive (+) RA, RF-negative (-) RA, ACPA (+) RA and ACPA (-) RA. The statistical significance of the summary OR was determined by using the *Z*-test. A *P* value greater than 0.10 for the *Q*-test indicated a lack of heterogeneity among the studies. In cases where significant heterogeneity was detected, the random effects model was used, otherwise the fixed effects model was used \[[@B29],[@B30]\]. We investigated the association between IL-21 variant and RA risk: the allelic contrast (T-allele versus G-allele), homozygote comparison (TT versus GG), dominant genetic model (TT+TG versus GG), heterozygote comparison (TG versus GG) and recessive genetic model (TT versus TG+GG). Funnel plot asymmetry was assessed using Begg's test and publication bias was assessed using Egger's test. In both tests *P* \< 0.05 was considered statistically significant \[[@B31]\]. HWE was evaluated using Pearson's chi-square (*χ*^2^) test, where *P* \< 0.05 was considered significant \[[@B32]\]. All statistical tests used in the present study were performed using Stata (version 11.0; StataCorp LP, College Station, TX). The power and sample size analysis of our meta-analysis was calculated by a program called PS: Power and Sample Size Calculation (<http://biostat.mc.vanderbilt.edu/wiki/Main/PowerSampleSize#Windows>) \[[@B33]\].

Results {#sec3}
=======

Characteristics of selected studies {#sec3-1}
-----------------------------------

A total of 23 published articles were retrieved from the PubMed database in accordance with our selection criteria. Among those, 11 articles were excluded for the following reasons: four articles were unrelated; five articles were excluded because they investigated diseases other than RA; one examined the *IL-23R rs11209026* polymorphism, and one did not have complete genotype's information, three articles were classified to meta-analysis. Following the above screening, the remaining nine articles, comprising a total of 9998 cases and 10,742 controls, were selected for the meta-analysis ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}) \[[@B9],[@B19]\]. Seven studies evaluated Caucasian subjects and the remaining two investigated Asian subjects. In addition, two of the studies included information about RF and ACPA status \[[@B20],[@B22]\]. All of the patients studied here were diagnosed according to the American College of Rheumatology's revised criteria \[[@B34]\]. The controls were unrelated, healthy individuals, who were age and ethnically matched. Polymorphisms were genotyped using TaqMan genotyping assays. Characteristics of *IL-21 rs6822844* G/T polymorphism studies are summarized in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. The genotype frequencies in the controls were in Hardy--Weinberg equilibrium, except in one study \[[@B20]\]. Finally, we confirmed that our analysis is of adequate statistical power (0.998). Finally, we checked the Minor Allele Frequency (MAF) reported for the five main worldwide populations in the 1000 Genomes Browser (<https://www.ncbi.nlm.nih.gov/snp/rs6822844#frequency_tab>): East Asian (EAS), 0.001; European (EUR), 0.1531; African (AFR), 0.0113; American (AMR), 0.0605; and South Asian (SAS), 0.0685 ([Figure 2](#F2){ref-type="fig"}). The MAF in our analysis was 0.1542 and 0.1790 in the case and control groups, respectively, both higher than the results from1000 Genomes Browser database.

![A flowchart illustrating the search strategy used to identify association studies for *IL-21 rs6822844* polymorphism and RA risk](bsr-40-bsr20191449-g1){#F1}

![T-allele frequencies for the *IL-21 rs6822844* polymorphism among cases/controls stratified by ethnicity\
Vertical line, T-allele frequency; Horizontal line, ethnicity type. EAS: East Asian; EUR: European; AFR: African; AMR: American; SAS: South Asian.](bsr-40-bsr20191449-g2){#F2}

###### Study characteristics from published studies on the relationship between *IL-21 rs6822844* polymorphism and RA risk

  Author           Year   Country       Ethnicity   Case   Control   SOC   Case   Control   HWE    Genotype   Quality Score   NOS                                 
  ---------------- ------ ------------- ----------- ------ --------- ----- ------ --------- ------ ---------- --------------- ------ -------- -------------- ---- ---
  Daha             2009   Netherlands   Caucasian   877    866       HB    116    53        708    126        73              667    \<0.01   MALDI-TOF-MS   6    6
  Zhernakova       2007   Netherlands   Caucasian   1012   924       PB    21     243       748    31         280             613    0.984    SNaPshot       8    8
  WTCCC            2007   U.K.          Caucasian   1856   2933      PB    61     553       1242   94         958             1881   0.035    GeneChip       10   7
  Maiti            2010   Turkey        Asian       354    368       HB    6      32        316    4          65              299    0.824    TaqMan         11   7
  Barton           2009   U.K.          Caucasian   3886   3454      HB    95     1052      2739   125        1003            2326   0.193    TaqMan         10   7
  Louahchi         2016   Algeria       Asian       323    323       PB    6      31        286    10         80              233    0.336    TaqMan         10   9
  Malinowski       2017   Poland        Caucasian   422    338       PB    6      103       313    4          79              255    0.438    TaqMan         10   9
  Teixeira         2009   France        Caucasian   434    434       PB    8      99        327    11         110             313    0.719    TaqMan         10   8
  Hollis-Moffatt   2010   New Zealand   Caucasian   834    1102      PB    30     221       583    29         330             743    0.285    TaqMan         11   8

Abbreviations: HB, hospital-based; HWE, Hardy--Weinberg equilibrium of control group; MALDI-TOF MS, polymerase chain reaction--matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; NOS, Newcastle--Ottawa Scale; PB, population-based; SOC, source of control.

###### RA characteristics from published studies on the relationship for *IL-21 rs6822844* polymorphism

  Author     Year   Ethnicity   Types     Case   Control   Case   Control                    
  ---------- ------ ----------- --------- ------ --------- ------ --------- ----- ----- ---- -----
  Louahchi   2016   African     ACPA^−^   73     323       9      9         55    10    80   233
  Daha       2009   Caucasian   ACPA^−^   228    866       8      60        160   126   73   667
  Louahchi   2016   African     ACPA^+^   258    323       6      26        226   10    80   233
  Daha       2009   Caucasian   ACPA^+^   327    866       25     52        250   126   73   667
  Daha       2009   Caucasian   RF^−^     250    866       20     38        192   126   73   667
  Louahchi   2016   African     RF^−^     101    323       1      7         93    10    80   233
  Daha       2009   Caucasian   RF^+^     487    866       55     53        379   126   73   667
  Louahchi   2016   African     RF^+^     222    323       5      23        194   10    80   233

Abbreviations: ACPA, anti-citrullinated protein antibody; RF, rheumatoid factor.

Pooled analyses {#sec3-2}
---------------

Overall, a significant protective association was observed between the variant genotypes of *IL-21 rs6822844* G/T and RA risk in all different genetic models. In the allelic contrast model \[OR = 0.81, 95% CI = 0.72--0,91, *P* value of heterogeneity test (*P*~h~) \< 0.001, *P* value of *z*-test \<0.001\] and complete dominant model \[OR = 0.78, 95% CI = 0.68--0.89, *P* value of heterogeneity test (*P*~h~) \< 0.001, *P* value of *z*-test \< 0.001\] ([Figure 3](#F3){ref-type="fig"}), and the dominant model \[OR = 0.96, 95% CI = 0.95--0.97, *P*~h~ = 0.123\] ([Table 3](#T3){ref-type="table"}).

![Forest plot of RA risk associated with *IL-21 rs6822844* polymorphism (T-allele versus G-allele) in the overall analysis\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](bsr-40-bsr20191449-g3){#F3}

###### Total and stratified analysis of *IL-21 rs6822844* polymorphism and RA risk

  Variables          *N*   Case/Control   T-allele versus G-allele   TG versus GG   TT versus GG   TT+TG versus GG     TT versus TG+GG                                                                                                                           
  ------------------ ----- -------------- -------------------------- -------------- -------------- ------------------- ----------------- --------- -------------------- --------- ------- ------------------- --------- --------- -------------------- --------- -------
  Total              9     9998/10742     0.81 (0.72--0.91)          \<0.001        \<0.001        0.76 (0.65--0.88)   \<0.001           \<0.001   0.81 (0.70--0.94)    0.176     0.005   0.78 (0.68--0.89)   \<0.001   \<0.001   0.85 (0.73--0.98)    0.205     0.027
  Ethnicity                                                                                                                                                                                                                                                      
  Asian              2     677/691        0.48 (0.37--0.63)          0.115          \<0.001        0.38 (0.28--0.53)   0.231             \<0.001   0.74 (0.34--1.62)    0.202     0.456   0.42 (0.31--0.56)   0.148     \<0.001   0.87 (0.40--1.89)    0.243     0.721
  Caucasian          7     9321/10051     0.87 (0.83--0.92)          0.202          \<0.001        0.86 (0.80--0.92)   0.331             \<0.001   0.81 (0.70--0.95)    0.134     0.005   0.85 (0.80--0.91)   0.335     \<0.001   0.85 (0.73--0.98)    0.143     0.029
  SOC                                                                                                                                                                                                                                                            
  HB                 3     5117/4688      0.84 (0.78--0.91)          0.218          \<0.001        0.69 (0.48--1.00)   0.011             0.050     0.76 (0.63--0.92)    0.202     0.004   0.77 (0.63--0.95)   0.073     0.017     0.78 (0.65--0.95)    0.181     0.012
  PB                 6     4881/6054      0.81 (0.67--0.97)          \<0.001        0.023          0.77 (0.62--0.94)   \<0.001           0.012     0.90 (0.71--1.13)    0.219     0.355   0.77 (0.63--0.95)   \<0.001   0.014     0.95 (0.76--1.19)    0.317     0.665
  Genotype methods                                                                                                                                                                                                                                               
  Others             3     3745/4723      0.83 (0.72--0.96)          0.067          0.010          0.81 (0.73--0.90)   0.151             \<0.001   0.86 (0.70--1.04)    0.229     0.128   0.82 (0.75--0.90)   0.123     \<0.001   0.90 (0.74--1.09)    0.293     0.273
  Taqman             6     6253/6019      0.78 (0.64--0.95)          \<0.001        0.015          0.73 (0.56--0.93)   \<0.001           0.012     0.76 (0.61--0.95)    0.164     0.014   0.74 (0.59--0.94)   \<0.001   0.012     0.79 (0.64--0.99)    0.167     0.037
  RF status                                                                                                                                                                                                                                                      
  RF+                2     709/1189       0.63 (0.32--1.24)          0.004          0.181          0.67 (0.19--2.43)   \<0.001           0.544     0.75 (0.54--1.04)    0.673     0.085   0.61 (0.24--1.53)   0.001     0.292     0.75 (0.54--1.03)    0.950     0.074
  RF-                2     351/1189       0.47 (0.15--1.46)          0.003          0.194          0.65 (0.08--5.44)   \<0.001           0.689     0.52 (0.32--0.84)    0.466     0.008   0.49 (0.11--2.22)   \<0.001   0.357     0.49 (0.31--0.80)    0.651     0.004
  ACPA status                                                                                                                                                                                                                                                    
  ACPA+              2     585/1189       0.60 (0.33--1.09)          0.010          0.096          0.80 (0.15--4.43)   \<0.001           0.801     0.54 (0.36--0.82)    0.786     0.004   0.62 (0.23--1.72)   \<0.001   0.362     0.52 (0.34--0.78)    0.454     0.002
  ACPA-              2     301/1189       0.94 (0.75--1.20)          0.196          0.635          1.31 (0.18--9.33)   \<0.001           0.786     0.99 (0.07--14.35)   \<0.001   0.993   1.25 (0.94--1.66)   0.128     0.121     0.96 (0.05--20.27)   \<0.001   0.977

*P*~h~: value of *Q*-test for heterogeneity test; *P*: *Z*-test for the statistical significance of the OR; ACPA: anti-citrullinated protein antibody;RF:rheumatoid factor; HB: hospital-based; PB: population-based; SOC; source of control

In the stratified analysis by ethnicity, a decreased association was observed both in Asian \[e.g. TG versus GG: OR = 0.38, 95% CI = 0.28--0.53, *P* value of heterogeneity test (*P*~h~) = 0.231, *P* value of *z*-test \<0.001\] and Caucasian populations \[TG versus GG: OR = 0.86, 95% CI = 0.80--0.92, *P* value of heterogeneity test (*P*~h~) = 0.331, *P* value of *z*-test \<0.001\] ([Figure 4](#F4){ref-type="fig"}) ([Table 3](#T3){ref-type="table"}).

![Forest plot of RA risk associated with *IL-21 rs6822844* polymorphism (TG versus GG) in the ethnicity subgroup\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](bsr-40-bsr20191449-g4){#F4}

In addition, in the stratified analysis by the source of the control, similar results were detected in both HB \[TT+TG versus GG: OR = 0.77, 95% CI = 0.63--0.95, *P* value of heterogeneity test (*P*~h~) = 0.073, *P* value of *z*-test = 0.017\] and PB \[TT+TG versus GG: OR = 0.77, 95% CI = 0.63--0.95, *P* value of heterogeneity test (*P*~h~) \< 0.001, *P* value of *z*-test = 0.014\] ([Figure 5](#F5){ref-type="fig"}) ([Table 3](#T3){ref-type="table"}).

![Forest plot of RA risk associated with *IL-21 rs6822844* polymorphism (TT+TG versus GG) in the source of control\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](bsr-40-bsr20191449-g5){#F5}

Several different methods were applied in the included studies. We therefore analyzed whether association was existed in variant methods, significant association was observed using TaqMan \[TT versus GG: OR = 0.76, 95% CI = 0.61--0.95, *P* value of heterogeneity test (*P*~h~) = 0.164, *P* value of *z*-test = 0.014\] ([Figure 6](#F6){ref-type="fig"}) ([Table 3](#T3){ref-type="table"})

![Forest plot of RA risk associated with *IL-21 rs6822844* polymorphism (TT versus GG) in the genotype methods subgroup\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](bsr-40-bsr20191449-g6){#F6}

Finally, in the stratified analysis by RF status, pooled associations were found among RF^−^ RA risk and *IL-21 rs6822844 G/T* polymorphism \[OR = 0.52, 95% CI = 0.32--0.84, *P*~h~ = 0.466, *P* = 0.008 for TT versus GG, and OR = 0.49, 95% CI = 0.31--0.80, *P*~h~ = 0.651, *P* = 0.004 for TT versus GG, [Figure 7](#F7){ref-type="fig"}\]. Similarly, significant associations were also detected in several models in ACPA+ status \[OR = 0.52, 95% CI = 0.34--0.78, *P*~h~ = 0.454, *P* = 0.002 for recessive model, [Figure 7](#F7){ref-type="fig"}\] ([Table 3](#T3){ref-type="table"}).

![Forest plot of RA risk associated with *IL-21 rs6822844* polymorphism (TT versus TG+GG) in the autoantibody subgroup (RF and ACPA status)\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.](bsr-40-bsr20191449-g7){#F7}

Publication bias and sensitivity analysis {#sec3-3}
-----------------------------------------

Begg's and Egger's tests were performed to assess publication bias. As shown in [Table 4](#T4){ref-type="table"}, neither of the tests provided any evidence of publication bias (T-allele versus G-allele: *t* = −1.47, *P* = 0.186 for Egger's test; and *z* = 1.15, *P* = 0.251 for Begg's test, [Figures 8](#F8){ref-type="fig"} and [9](#F9){ref-type="fig"}). Sensitivity analysis was performed to assess whether individual studies influenced the pooled ORs by sequential removal of individual studies. The results suggested that no single study significantly affected the overall OR ([Figure 10](#F10){ref-type="fig"}).

![Begg's funnel plot for publication bias test (T-allele versus G-allele)](bsr-40-bsr20191449-g8){#F8}

![Egger's publication bias plot (T-allele versus G-allele)](bsr-40-bsr20191449-g9){#F9}

![Sensitivity analysis between *IL-21 rs6822844* polymorphism and RA risk (T-allele versus G-allele)](bsr-40-bsr20191449-g10){#F10}

###### Publication bias tests (Begg's funnel plot and Egger's test for publication bias test)

  Egger's test               Begg's test                                                   
  -------------------------- ------------- ------- ------- ------- ---------------- ------ -------
  T-allele versus G-allele   −1.883        1.283   −1.47   0.186   (−4.918,1.152)   1.15   0.251
  TG versus GG               −1.427        1.049   −1.36   0.261   (−3.906,1.053)   1.36   0.175
  TT versus GG               −0.534        0.413   −1.29   0.237   (−1.511,0.443)   0.73   0.466
  TT+TG versus GG            −1.671        1.157   −1.44   0.192   (−4.407,1.063)   0.94   0.348
  TT versus TG+GG            −0.535        0.414   −1.29   0.237   (−1.514,0.443)   0.94   0.348

for *IL-21 rs6822844* polymorphism.

Discussion {#sec4}
==========

To our knowledge, RA is a systemic, inflammatory autoimmune disorder with numerous symptoms caused by an intricate chain of physiological events \[[@B35]\]. Tumor necrosis factor α and interleukin family (such as interleukin 1β, interleukin 17 and interleukin 21) are some of the key mediators of RA pathogenesis \[[@B36]\]. In recent years, *IL-21* has been found to be a key player in RA pathogenesis and progression \[[@B37]\]. In RA pathogenesis, IL-21 receptor (IL-21R) is highly expressed in CD4+ T cell subsets, macrophages, dendritic cells and synovial fibroblasts \[[@B40]\]. These immune cell subtypes recognize the IL-21 in the microenvironment and carry out several intricate chains of events \[[@B41]\]. IL-21 has been implicated to be an important target in RA therapy, and several studies have substantiated its role through activation of signaling pathways and in promoting inflammatory condition \[[@B42],[@B43]\].

The Wellcome Trust Case Control Consortium (WTCCC) first designed and analyzed GWAS studies, comprising 2000 cases and 3000 shared controls, and found a significant association between a common haplotype located in the 3′-untranslated region of *IL-21* and susceptibility to RA \[[@B9]\]. Following this, several studies re-analyzed this association using a greater number of samples to increase statistical power, in addition to including other predictors, such as RF and ACPA status and levels. However, results have been controversial. Zhernakova et al. \[[@B26]\] detected a decrease in frequency of the *rs6822844* T-allele in RA (14.1%), and demonstrated significant association between this polymorphism and RA susceptibility (OR = 0.72, 95% CI = 0.61--0.86, *P* \< 0.001). Moreover, Louahchi et al. \[[@B22]\] showed a protective effect of the minor T-allele (OR = 0.39, 95% CI = 0.26--0.57), whereas the major G-allele appeared to be a risk susceptibility (OR = 2.57, 95% CI = 1.74--3.83, *P* \< 0.001). Nevertheless, Malinowski et al. \[[@B24]\] examined 422 RA cases and 338 controls, and found that *IL-21 rs6822844* was not risk loci for RA susceptibility.

To our knowledge, the present study was combined to investigate whether there has an association between *IL-21 rs6822844* polymorphism and RA risk. We performed a meta-analysis involving 9998 RA cases and 10742 controls. The main finding of our study was that *rs6822844* T-allele was a protective factor for individuals carrying this allele, in other words, the *rs6822844* polymorphism in Asian and Caucasian populations may decrease RA susceptibility in these ethnic groups. If an individual carries the IL-21 *rs6822844* T-allele, he/she may have a lower risk to become RA patient than G-allele, in contrast, G-allele carries may have a higher risk to become RA. Through detected this polymorphism, we may know the susceptibility of RA for one person in advance, which may be helpful or make sense in the future. Our results suggest that the *rs6822844* polymorphism influenced not only the RF status, but also the presence of ACPA. Determination of any genetic differences between RF and ACPA status in RA patients may shed light on their roles in RA pathogenesis. Such data may be useful in the clinical diagnosis and prevention of RA, as well as for identifying therapeutic targets in the treatment of RA patients. Recently, Mohammadi et al. also made Bayesian meta-analysis about polymorphisms of inflammatory cytokines and RA risk; however, positive results were found about genetic polymorphisms of IL23R gene, but not IL-21 and IL17A genes. Moreover, RF and ACPA status were not involved \[[@B44]\], which were the different and innovate about present study.

Although the results reported here were statistically significant, there are some limitations in our study should be mentioned. First, the number of publications included remains insufficient for a comprehensive analysis. Second, gene--gene and gene--environment interactions were not taken into consideration here. In addition, other covariates including age, sex, family history, environmental factors, disease stage and lifestyle also should be included. Third, the distribution of the ethnicity and source of control categories was not balanced, especially in Asian populations and HB. Fourth, the number of studies reporting RF and ACPA status was not very large. Fifth, following items: the correlation of *IL-21 rs6822844* polymorphism with the stages of arthritis; the protein expression level of IL-21 in different polymorphisms should also be added and be re-analyzed by meta in the future research. Sixth, IL-12 gene contains many SNPs, in our included nine studies, three studies contained two or more SNPs, for example Malinowski et al., (2016) contained *rs6822844, rs2221903, rs6840978* and *rs2285452*; Teixeira et al., (2009) contained not only *rs6822844*, but also *rs4505848, rs11732095, rs4492018*, and *rs1398553*; Hollis-Moffatt et al., (2010) contained only *rs6822844* and *rs907715*. Thus, we can't analyze the existed interaction between the SNPs in the same IL-21 gene. Despite these limitations, some advantages should also be mentioned. First, all selected studies were published after 2008, which may be indicative of the increasing attention that this topic has garnered in recent years. Second, the coverage of RA features in this meta-analysis was more extensive. Third, our study combined the highest number of individuals so far, the power of our meta-analysis was greater than 0.95, which suggested that the data were trustworthy.

In summary, our study presented evidence that *IL-21 rs6822844* polymorphism was associated with significantly decreased RA risk and that the RF autoantibody may be considered as a biomarker for the detection of RA susceptibility.
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